Biomedical subjects

L Qin

Publications and source records attributed to L Qin.

At least 163 records · Page 9Linked to original sources

PubMed1995

Effect of schisanhenol on function and surface shape of rat neutrophils.

AIM: To study the regulatory effect of Schisanhenol (Sal) on function of rat neutrophils. RESULTS: It was found that Sal (1, 10, and 100 mumol.L(-1)) inhibited neutrophil activities such as chemotaxis, phagocytosis, and superoxide anion production in vitro in a concentration-dependent manner. Changes of surface morphology of neutrophils were observed by scanning electron microscopy, showing that the ruffles and pseudopods on neutrophil surface increased under the stimulation by chemotactic peptide N-formyl-Met-Leu-Phe (FMLP). When pretreated with Sal 100 mumol.L(-1), the ruffles and pseudopods disappeared and the surface became smooth. Sal 100 mumol.L(-1) decreased the cytosolic calcium concentration of neutrophils and increased the intracellular cAMP level. CONCLUSION: These data suggested that Sal could inhibit the function of rat neutrophils through affecting the cytosolic free calcium and cAMP level besides its anti-oxidant activity.

Animals↗

PubMed1995

[The relation between p53 mutations and tumor invasiveness of human hepatocellular carcinoma].

We have combined the polymerase chain reaction (PCR) with the HaeIII enzyme restriction analysis to study the mutations at codon 249 of p53 gene in L02 human liver cell line, Bel-7402, SMMC-7721 human hepatocellular carcinoma cell lines and 19 surgical specimens of hepatocellular carcinoma (HCC) and their surrounding non-cancer liver tissues. None of the three cell lines and the non-cancer liver tissues was found to have p53 mutation; but 10 of 19 HCC samples (52.6%) had p53 point mutations, and the p53 gene mutated more frequently in HCC with incomplete capsule, intrahepatic metastasis, or multiple nodules than in those with well encapsulated (70% vs 33.3%, P < 0.05), no intrahepatic metastasis (71.4% vs 41.6%, P < 0.05) and single nodule (83.3% vs 38.5%, P < 0.05). These suggested that the codon 249 was a mutational hotspot of the p53 gene in human HCC seen in China, and p53 mutations may be related to invasiveness of human HCC.

Base Sequence↗

PubMed1994

CTLA4Ig prolongs allograft survival while suppressing cell-mediated immunity.

T cell activation is the result of antigen-specific interactions with the TCR/CD3 complex and costimulation via other T cell surface receptors. Prevention of costimulation can result in clonal anergy. CTLA4Ig is a fusion protein that binds with high-affinity to the B7/BB1 ligand and blocks the interaction of this ligand with CD28 and CTLA4. We explored the immunosuppressive effects of CTLA4Ig in a murine nonvascularized heterotopic cardiac transplant model and in a model of cell mediated immunity. CTLA4Ig administered in vivo for two days at the time of transplantation resulted in significant prolongation of allograft survival (55 +/- 2.0 vs. 12.2 +/- 0.5 days for control, P < 0.03). Administration at later times or to previously primed animals produced no prolongation of graft survival. CTLA4Ig administered during in vivo immunization to the hapten TNP suppressed the contact sensitivity response and inhibited the subsequent in vitro generation of secondary TNP-specific CTL. CTLA4Ig administered in vivo had no effect on subsequent primary alloantigen-specific CTL or MLR responses--however, when added to culture the fusion protein inhibited the MLR response by 80%, but not the alloantigen-specific CTL response. CTLA4Ig inhibited CD4+ and CD8+ proliferative and cytokine responses to alloantigen. Flow cytometry showed no changes in distribution of subpopulations of T cells. These results confirm the immunosuppressive activity of CTLA4Ig in vivo in an allograft model and show that both CD4+ and CD8+ T cells are suppressed by CTLA4Ig. The most efficacious time of administration is during priming of the immune response at the time of antigen presentation.

Abatacept↗

PubMed1994

Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors.

We have developed an immunotherapeutic approach with potential application in the treatment of viral and malignant disease. We show that primary CD8+ T cells isolated from peripheral blood can be genetically modified by retroviral transduction to express high levels of universal (major histocompatibility complex-unrestricted) chimeric T-cell receptors specific for human immunodeficiency virus (HIV) antigens. Two classes of HIV-specific URs in which the antigen-binding domain is comprised of either CD4 or a single-chain antibody are capable of activating a number of T-cell effector functions in response to target cells, including cytolysis, in a highly sensitive and specific manner. Importantly, we have addressed a number of issues which, although particularly relevant to the clinical application of this approach in the treatment of HIV infection, may also impact on the potential of UR immunotherapy for other disease targets. The UR immunotherapeutic system is particularly suited for evaluation in the clinical setting.

Animals↗

PubMed1994

Photoinduced electron transfer from the triplet state of zinc cytochrome c to ferricytochrome b5 is gated by configurational fluctuations of the diprotein complex.

The intracomplex electron-transfer reaction 3Zncyt/b5(III)-->Zncyt+/b5(II) within electrostatic and covalent complexes of zinc(II) cytochrome c and ferricytochrome b5 is studied by laser flash photolysis. Kinetic effects of protein cross-linking and of solution viscosity are interpreted in terms of dynamic mobility of the associated proteins with respect to each other. The rate constant for the monoexponential reaction in the electrostatic complex is 3.5 x 10(5) s-1 in aqueous solution; this value is independent of protein concentration and ionic strength, but it decreases markedly as viscosity is raised by addition of glycerol or sucrose. The multiexponential reaction in the covalent complex was analyzed also in terms of the stretched exponential, exp[-(kt)n]. The best fit requires k = 6.8 x 10(4) s-1 and n = 0.56 in aqueous solution; this rate constant is independent of protein concentration and ionic strength, but it decreases slightly as viscosity is raised. Fitting of the viscosity dependence to a simple two-state kinetic model yields a rate constant of 3.0 x 10(5) s-1 for rearrangement of the electrostatic complex 3Zncyt/b5(III) from the initial docking configuration to a different, more reactive, configuration. The corresponding rate constant for rearrangement of the electrostatic complex 3Zncyt/pc(II) containing plastocyanin, determined previously, is 2.5 x 10(5) s-1. Evidently, the intracomplex reaction in both electrostatic complexes is gated by a rearrangement process.(ABSTRACT TRUNCATED AT 250 WORDS)

Cytochrome c Group↗

PubMed1994

Anti-CD2 mAbs suppress cytotoxic lymphocyte activity by the generation of Th2 suppressor cells and receptor blockade.

The mechanism by which anti-CD2 mAbs inhibit hapten-specific and alloantigen specific CTL was explored. In vivo administration of alpha-CD2 mAbs resulted in 80 to 100% inhibition of alloantigen specific CTLs. Mixing cells from control animals with cells from alpha-CD2-treated groups demonstrated transferable suppression of CTL (40-67% suppression). These suppressor cells were CD4+CD8- and associated with increased IL-4 and TGF-beta in culture as compared with controls. Anti-CD2 mAbs added at the initiation of culture resulted in 60 to 72% inhibition of trinitrophenyl-CTL, whereas mAbs added at the time of assay resulted in less than 50% inhibition of trinitrophenyl-CTLs. F(ab')2 and Fab alpha-CD2 produced inhibition similar to intact mAbs when added at the time of the lytic assay, whereas both produced only modest inhibition in vivo or when added at the initiation of culture. Alloantigen-specific CTLs were not affected by Ab addition to either culture or assay. The immunosuppressive effects were generalizable because a panel of alpha-CD2 mAbs were all comparably effective in suppressing hapten-specific CTLs when administered in vivo. The results demonstrate that the inhibitory effects are the result of blockade of receptor adhesion function during Ag priming or target recognition, Fc-related effects, and the generation of a negative regulatory, CD4+CD8-, IL-4- and TGF-beta-producing TH2 suppressor T cell.

Animals↗

PubMed1994

Anti-CD2 monoclonal antibodies synergize with FK506 but not with cyclosporine or rapamycin to induce tolerance.

CsA, FK506, and rapamycin prolong allograft survival; however, each has significant associated side effects at therapeutic doses. Anti-CD2 mAbs also prolong survival but without toxicity. We tested whether alpha CD2 mAbs in combination with subtherapeutic immunosuppression could prolong allograft survival in a synergistic fashion. C57BL/6 (H-2b) mouse hearts were transplanted to CBA (H-2k) mice in a heterotopic, non-vascularized cardiac allograft model. Recipients received immunosuppressants intraperitoneally for 14 days and/or alpha CD2 mAb intravenously for 2 days starting at the time of grafting. Survival was determined by electrocardiogram monitoring. Anti-CD2 alone prolonged survival to 22.4 +/- 1.0 days versus 13.4 +/- 0.5 days for untreated controls (P < 0.05), while low dose FK506 minimally prolonged survival to 16.7 +/- 0.7 days (P < 0.057). However, FK506 plus alpha CD2 resulted in synergistic prolongation of graft survival to 28.0 +/- 2.1 days. Several doses of CsA and rapamycin in combination with alpha CD2 did not prolong survival over alpha CD2 administered alone. A 60-day course of low dose FK506 plus alpha CD2 resulted in indefinite graft survival (> 165 days). These animals were tolerant since they accepted a second donor-specific graft. CTL and MLR activity in long-term recipients were normal to both donor-specific and third party alloantigen. The combination of alpha CD2 with low dose FK506 is synergistic in prolonging cardiac allograft survival, while combinations with CsA and rapamycin are not. Continuous administration of low dose FK506 plus alpha CD2 results in a state of tolerance. This suggests that FK506 acts at a different locus in allograft immunity compared with the other immunosuppressants and this may be related to the alternative CD2 T cell activation pathway.

Animals↗

PubMed1994

Anti-CD2 receptor and anti-CD2 ligand (CD48) antibodies synergize to prolong allograft survival.

Indefinite graft survival was obtained with murine cardiac allografts using the combined administration of monoclonal antibodies (mAbs) directed against the receptor ligand pair CD2-CD48. Although each antibody could prolong graft survival when given alone, neither resulted in the indefinite graft survival seen with the combination. Combined mAb administration is associated with inhibition of T cell priming and help and subsequent cytotoxic T lymphocyte generation. This indicates that the interaction between CD2 and its ligand is important for antigen priming and recognition, and combined mAbs may prove to be a useful therapeutic regimen for transplantation.

Animals↗

PubMed1994

kat: a high-efficiency retroviral transduction system for primary human T lymphocytes.

We describe a novel retroviral packaging system in which high titer amphotropic retrovirus was produced without the need to generate stable producer clones. kat expression vectors, which produce high levels of retroviral vector transcripts and retroviral packaging functions, were transfected into 293 cells followed by virus harvest 48 hours posttransfection. Viral titers as high as 3.8 proviral copies/cell/mL of frozen supernatant in 3T3 cells were obtained, 10- to 50-fold greater than transient viral titers reported using 3T3-based retroviral packaging lines. Cocultivation of primary human CD8+ T lymphocytes after transient transfection of 293 cells with kat plasmids resulted in transduction efficiencies of 10% to 40%, 5- to 10-fold greater compared to cocultivation with a high titer PA317 producer clone and significantly greater than previously reported results for transduction of primary human T lymphocytes with retroviral vectors. Virus produced using the kat system was shown to be free of detectable replication competent retrovirus by an extended provirus mobilization assay, demonstrating that this system is as safe as currently available stable packaging lines. The kat virus production system should be of general use for the rapid production of high titer viral supernatants, as well as for high-efficiency transduction hematopoietic cell types refractory to retroviral transduction.

3T3 Cells↗

PubMed1994

Design of a cryogenic videocamera-recorder and image processing system and calculation of volumes of red cells.

Since Rowe reported that the storage technique for red cells at very low temperatures had been realized successfully, many experts who work in the fields of cryobiology and medicine have turned their attention to this storage technique for tissues and organs. Since the first quantitative cryomicroscope was made successfully about 20 years ago, it has been possible to observe changes in shape and phase. Particularly the image processing technique has laid the foundation for quantitative analysis of the relationship between changes in shape and damage from freezing of cells and cooling rate and storage temperature. In this work, we constructed a system consisting of a cryomicroscope, a videocamera-recorder, and an image processor. We carried out many experiments with red cells in cold storage and have established a model for calculating the volumes of red cells. In our experiments we also dynamically traced the shape changes of cells with various experimental parameters.

Blood Preservation↗

PubMed1994

Anti-CD48 (murine CD2 ligand) mAbs suppress cell mediated immunity in vivo.

With the identification of murine CD48 as a homolog of the human CD2 ligand LFA-3 (CD58) and as a ligand itself for murine CD2, the anti-murine CD48 mAb HM48-1 was administered intravenously to investigate the role of CD48 in cell mediated immunity in vivo. Anti-CD48 mAb diminished the contact sensitivity response to the hapten trinitrophenol (TNP). mAb also inhibited in vivo priming for the subsequent generation of secondary, TNP-specific, cytotoxic T lymphocytes (CTL) in vitro. The inhibitory effect was most effective in the afferent or inductive phase of immunity for CTL, while anti-CD48 mAb was most inhibitory for the efferent or elicitative phase of contact sensitivity. Addition of anti-CD48 mAb directly to secondary CTL cultures also completely inhibited CTL generation, while addition to the lytic assay showed only minimal inhibition of CTL activity. Combining cells from mAb treated and untreated animals showed no evidence for suppressor cells. Further experiments revealed that mAb administered in vivo, as well as to culture, inhibited development of primary, alloantigen-specific CTL in vitro. Mixed lymphocyte reaction and phytohemagglutinin proliferation were partially suppressed by mAb administered in vivo or in vitro, whereas other mitogenic responses remained unaffected. Flow cytometric analysis revealed a moderate down modulation of CD48, CD3 and CD8 after treatment with anti-CD48. However, this did not represent T cell depletion since CD2, Thy-1.2 and Ig expression did not change. These results support a major unrecognized role for CD48 in diverse aspects of cell mediated immunity, affecting both CD4+ and CD8+ effector T cell function.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗

PubMed1994

Gene transfer for transplantation. Prolongation of allograft survival with transforming growth factor-beta 1.

OBJECTIVE: The authors tested the ability of plasmid gene transfer to express transforming growth factor-beta 1 (TGF-beta 1), prolong allograft survival, and evaluate promoter effects on gene expression. SUMMARY BACKGROUND DATA: Delivery of immunosuppressants directly to allografts using gene transfer and gene therapy approaches may inhibit immune activation while avoiding the systemic toxicity of conventional immunosuppression. Candidate genes include soluble cytokines, which could be expressed at low levels throughout the graft while inducing a local immunosuppressive effect. Transforming growth factor-beta 1 is a soluble cytokine that has pleiotropic immunosuppressive effects. METHODS: Cardiac grafts from syngeneic (CBA/J, H-2k) or allogenic (C57BL/6, H-2b) donors were placed into CBA/J recipients. Purified plasmid DNA-encoding murine TGF-beta 1 or beta-galactosidase (Lac Z) under the control of RSV, SV40, MMTV, or pancreatic elastase promoters was injected into grafts at surgery. The Lac Z expression was determined by histologic examination and TGF-beta 1 expression by graft survival. Cytotoxic T lymphocyte and flow cytometric analyses were performed to evaluate the immunosuppressive effects of TGF-beta 1 in vitro. RESULTS: Plasmid DNA-encoding TGF-beta 1 prolonged survival from 12.6 +/- 1.1 days to 26.3 +/- 2.5 days (p < 0.02, Student's t test). The SV40 promoter was superior to the MMTV promoter in its ability to prolong survival. The effects of the plasmids were specific because Lac Z, antisense TGF-beta 1 inserts, or pancreatic elastase promoter did not prolong allograft survival. Histologic examination demonstrated Lac Z expression at least 14 days post-transplant in myocardial cells. Both RSV and SV40 promoters were effective in this respect, while a control null promoter was not. Toxicity testing showed that gene transfer of TGF-beta 1 did not alter survival or histology of syngeneic grafts. In addition, plasmids and purified TGF-beta 1 protein were not toxic to myoblasts in vitro. Recombinant TGF-beta 1 inhibited cytotoxic T lymphocyte generation and altered T cell surface receptor expression and subset expansion in vitro. CONCLUSION: Gene transfer/therapy with plasmid DNA encoding TGF-beta 1 in vivo achieves immunologic effects that prolong allograft survival. Multiple promoters effectively induce plasmid expression, which is achieved in cardiac myocytes for at least 2 weeks without toxicity or adverse systemic effects. Transforming growth factor-beta 1 inhibits immune responses by different mechanisms, revealed by in vitro analysis of T cell cytolytic function, subset distribution, and receptor display.

Animals↗

PubMed1993

Combined anti-CD2 and anti-CD3 receptor monoclonal antibodies induce donor-specific tolerance in a cardiac transplant model.

Administration of mAb against either the CD2 or CD3 receptor prolongs graft survival in CBA recipients in a heterotopic, nonvascularized cardiac transplant model, whereas the combination of mAb produces indefinite survival. Combined alpha-CD2 plus alpha-CD3 mAb synergistically prolonged allograft survival indefinitely for C57BL/6 donor hearts (> 150 vs 13.4 +/- 0.5 days for controls, p < 0.001, Wilcoxon's sign rank). All second donor-specific C57BL/6 allografts survived > 100 days (p < 0.001) without any additional immunosuppression. Third-party BALB/c allografts were rejected in a first set fashion (14.2 +/- 0.5 days). Anti-CD2 mAb of other epitopic specificities and isotypes demonstrate equivalent immunosuppressive capacity. The combination of mAb resulted in indefinite graft survival in other strain combinations. Therefore, these results are not restricted to a particular alpha-CD2 mAb or MHC combination. Combinations of alpha-CD2 plus mAb with specificities other than to CD3 did not result in tolerance, showing that the CD2-CD3 interaction was critical for tolerance induction. CTL and MLR responses from tolerant animals were normal both to H-2b and H-2d stimulators, indicating that clonal deletion of effector T cells did not occur. Adoptive transfer of naive recipient type cells broke tolerance, showing that graft adaptation was not the major determinant of tolerance maintenance. Flow cytometric analysis demonstrated that tolerance was not associated with deletion of T cells. The results imply that the mechanism of tolerance induction is related to suppression and/or anergy of helper and effector cells at the time of allografting, whereas maintenance of tolerance is associated with anergy in the Th cell compartment.

Animals↗

PubMed1993

Importance of protein rearrangement in the electron-transfer reaction between the physiological partners cytochrome f and plastocyanin.

Cytochrome f from turnip and plastocyanin from French bean were noninvasively cross-linked in the presence of the carbodiimide EDC so that the exposed heme edge in the former protein abuts the acidic patch remote from the copper site in the latter [Morand, L.Z., Frame, M.K., Colvert, K.K., Johnson, D.A., Krogmann, D.W., & Davis, D.J. (1989) Biochemistry 28, 8039]. The molecular mass, reduction potentials, and UV-visible and ESR spectra of the covalent complex were consistent with the composition cyt/pc and with a lack of noticeable structural perturbations of the protein molecules. Isoelectric focusing showed the presence of N-acylurea groups, byproducts of the cross-linking reaction [Zhou, J.S., Brothers, H.M. II, Neddersen, J.P., Peerey, L.M., Cotton, T.M., & Kostić, N.M. (1992) Bioconjugate Chem. 3, 382]. Laser flash spectroscopy, with riboflavin semiquinone as the reductant, showed that the electrontransfer reaction within the covalent complex cyt(II)/pc(II) is either undetectably slow or reversible. The question was resolved by monitoring, during redox titrations, the 1H NMR line widths of the heme methyl groups in free ferricytochrome f and in this protein cross-linked to plastocyanin.(ABSTRACT TRUNCATED AT 250 WORDS)

Cross-Linking Reagents↗

PubMed1993

Combination anti-CD2 and anti-CD3 monoclonal antibodies induce tolerance while altering interleukin-2, interleukin-4, tumor necrosis factor, and transforming growth factor-beta production.

OBJECTIVE: These studies were designed to elucidate the mechanism by which signals delivered by anti-CD2 monoclonal antibody (MoAb) interfere with activational signals delivered by anti-CD3 MoAb and induce long-term graft survival and tolerance. SUMMARY BACKGROUND DATA: Anti-CD2 or anti-CD3 MoAb can prolong allograft survival when administered alone. In combination, they synergistically prolong survival while reducing anti-CD3-associated cytokine toxicity. It was postulated that the mechanism of synergism and reduced cytokine toxicity was related to anti-CD2-induced alterations in anti-CD3-induced T-cell activation. METHODS: C57BL/6 (H-2b) mouse hearts were transplanted to CBA (H-2k) mice. The recipients received anti-CD2 and/or anti-CD3 MoAb intravenously only at the time of initial allografting. Serum from treated animals and culture supernatants from lymphocytes stimulated in vitro with anti-CD3 were examined for interleukin (IL)-2, -4, -6, and -10, tumor necrosis factor (TNF), and transforming growth factor-beta (TGF beta). RNA was isolated from lymphocytes from treated animals and examined for receptor and cytokine gene expression by northern hybridization or reverse transcribed and amplified by the polymerase chain reaction (PCR). RESULTS: Anti-CD2 and anti-CD3 MoAbs alone prolonged graft survival (22.0 +/- 0.5 days and 28.0 +/- 0.5 days, respectively; p < 0.02 and p < 0.01 vs. control, by Wilcoxon signed-rank test). Combined anti-CD2/anti-CD3 MoAbs synergistically prolonged survival indefinitely (> 150 days, p < 0.01) while decreasing cytokine toxicity. Second donor-specific allografts also showed long-term survival. The peak serum TNF concentration (2100 units/mL) was reduced 78% by anti-CD2 treatment (455 units/mL). Anti-CD2 inhibited anti-CD3-stimulated proliferation and in vitro production of IL-2 and IL-4, with no alteration of IL-6, IL-10, or TNF. Conversely, there was an increase in the immunosuppressive cytokine TGF beta. PCR analysis showed that anti-CD2 reduced anti-CD3-stimulated IL-2 messenger RNA expression, and by northern analysis, anti-CD2 inhibited anti-CD3-stimulated increases in messenger RNA for the CD2 and CD3 receptors themselves. CONCLUSIONS: The combination of anti-CD2 and anti-CD3 MoAbs induced a state of tolerance while decreasing anti-CD3-associated cytokine toxicity. The mechanism was related to anti-CD2-generated alterations in T-cell activation and gene expression.

Animals↗

PubMed1993

Anti-CD2 and anti-CD3 monoclonal antibodies synergize to prolong allograft survival with decreased side effects.

Anti-CD3 monoclonal antibody suppresses immunity and prolongs allograft survival; however, it induces T cell activation and overproduction of soluble factors that result in a deleterious cytokine syndrome. Anti-CD2 mAb also prolongs allograft survival, by suppression of mature and precursor CD4 and CD8 T cells and NK cells, without an associated cytokine release. Because of the close physical and functional association of CD2 and CD3 on the T cell surface, we tested whether alpha CD2 mAb in combination with alpha CD3 mAb could act synergistically to prolong allograft survival, and whether the combination would affect the alpha CD3-associated cytokine syndrome. C57BL/6 (H-2b) hearts were transplanted to CBA (H-2k) recipients in a heterotopic nonvascularized model. Recipients received alpha CD2 (12-15) or alpha CD3 (145-2C11) mAb i.v. alone or in combination. Lymphocytes from treated animals were also analyzed by fluorescent flow cytometry and stimulated in vitro and assessed for proliferation and lymphokine production. Anti-CD2 and alpha CD3 each prolong allograft survival (mean survival time 22.4 +/- 1.0 and 27.4 +/- 3.3 days, respectively vs. 14.0 +/- 0.6 for control mAb, P < 0.001 for both vs. control). Combinations of mAbs show a more complicated interaction. Very low doses (1 microgram) of alpha CD2 and alpha CD3, which have no effect when given alone, are synergistic (16.5 +/- 1.3 days, P < 0.02). A high dose of alpha CD2 (100 micrograms), which is immunosuppressive, is additive with a moderate dose of alpha CD3 (10 micrograms), which is immunostimulatory. The two mAbs are again synergistic when a high dose of alpha CD2 (100 micrograms) is combined with a high dose of alpha CD3 (1 mg) (> 51.5 +/- 23.0 days, P < 0.001). Furthermore, high-dose alpha CD2 administered 48 h prior to high-dose alpha CD3 was a more effective combination for prolonging allograft survival than both antibodies administered simultaneously (67.1 +/- 10 vs. 35.8 +/- 0.7 days, P < 0.05). Anti-CD2 also diminishes the alpha CD3-associated cytokine syndrome, and prior in vivo treatment with alpha CD2 decreases the subsequent in vitro proliferative response to alpha CD3 and the alpha CD3-stimulated production of IL-2 and IL-4. Flow cytometry demonstrates that in general these mAbs do not deplete but leave T cell populations intact with altered receptor expression. These results show that the combination of alpha CD2 and alpha CD3 mAbs prolongs cardiac allograft survival in a synergistic fashion while decreasing the side effects of alpha CD3 mAb alone.(ABSTRACT TRUNCATED AT 400 WORDS)

Animals↗

PubMed1993

Field evaluation of bednets impregnated with deltamethrin for malaria control.

Trials were undertaken in a hypoendemic area of malaria in an area bordering Vietnam, in Napo County of Guangxi Zhuang Autonomous Region, China. The aim was to compare the relative cost effectiveness of DDT residual spraying and of bednets impregnated with deltamethrin in the malaria control program. The trials were divided into three subgroups: (1) two farming areas and one coal mining area with a total population > 20,000, where the trial consisted of mass bednets impregnated with deltamethrin 15 mg/m2 net surface once a year, (2) one farming area with a population of approximately 3,600 where DDT residual spraying at 2g/m2 was carried out twice a year in May and August; (3) one farming area and one coal mining village with a population of > 4,000 were used as a control. The malaria vector population consisted mainly of Anopheles minimus and An. anthropophagus with a small contribution from An. sinensis. After bednets were impregnated with deltamethrin the mosquitos resting on the surface of the bednets decreased significantly, although there was less effect on the total vector population. The results showed that malaria incidence decreased significantly both in areas where impregnated bednets were used and in areas where residual spraying was undertaken. The positive IFAT rates of residents who slept under impregnated bednets decreased significantly in farming areas, especially in that area where bednet impregnation as a vector control measure had been undertaken for two years, but there was no change in the IFAT rate in DDT sprayed or control areas.(ABSTRACT TRUNCATED AT 250 WORDS)

Bedding and Linens↗

PubMed1993

[Phylogenesis of the extracellular matrix].

The extracellular matrix constitutes a highly organized intercellular medium. In multicellular animals, it plays important functions for cell cohesion and for the modulation of cell differentiation and behaviour as well. All the investigations conducted in non-vertebrate species have shown that the extracellular matrix is present at the onset of the multicellular life and throughout the animal kingdom. The collagen fibrils are the most constant element. Recent data on the structure of fibrillar collagen molecules and on the organization of the corresponding genes, obtained in sponges and sea-urchins have shown the remarkable conservation of these fibrillar collagens during evolution. This even emphasize their very likely fundamental function. These results, associated with data provided by morphological and biochemical informations obtained in cnidarians suggest that these primitive fibrillar collagens are the direct precursors of some vertebrate minor fibrillar collagens such as type V. Other collagens, with interrupted triple helix, are more variable and their characterization in sponges leads to consider these non-fibrillar collagens as precursors of basement membrane collagens, of fibril-associated collagens (the FACITs collagens), of the so-called "epithelial" collagens. They were probably used as sticking devices, anchoring the animal to its substratum, or as covering layers (cuticles, sheaths), and even as skeletons (i.e. the bath sponge). Adhesive molecules of higher animals ensure the mediation of the interactions between cells (via their membrane receptors of the integrin type) and the fibrous network of the extracellular matrix. It is the same situation at the beginning of the evolution of the multicellular animals where fibronectin, tenascin and then laminin are present. Proteoglycans too are components of primitive extracellular matrices. At last, only collagen mineralized by calcium phosphate (in bone) and elastin (in elastic fibers and laminae) seem to be restricted to vertebrates.

Animals↗